Skip to main navigation Skip to search Skip to main content

Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164

  • Dung T. Le*
  • , Tae Won Kim
  • , Eric van Cutsem
  • , Ravit Geva
  • , Dirk Jäger
  • , Hiroki Hara
  • , Matthew Burge
  • , Bert O’Neil
  • , Petr Kavan
  • , Takayuki Yoshino
  • , Rosine Guimbaud
  • , Hiroya Taniguchi
  • , Elena Elez
  • , Salah Eddin Al-Batran
  • , Patrick M. Boland
  • , Todd Crocenzi
  • , Chloe E. Atreya
  • , Yi Cui
  • , Tong Dai
  • , Patricia Marinello
    • Luis A. Diaz, Thierry André
*Corresponding author for this work
  • Johns Hopkins University
  • University of Ulsan
  • KU Leuven
  • Tel Aviv Sourasky Medical Center
  • Nationales Centrum Tumorerkrankungen
  • Saitama Cancer Center
  • Royal Brisbane and Women's Hospital
  • Indiana University Health
  • McGill University
  • National Cancer Center Japan
  • CHU de Toulouse
  • Aichi Cancer Center Hospital and Research Institute
  • Vall d’Hebron Research Institute
  • Krankenhaus Nordwest, Frankfurt am Main
  • Roswell Park Cancer Institute
  • Providence Cancer Center
  • University of California at San Francisco
  • Merck
  • Memorial Sloan-Kettering Cancer Center
  • Sorbonne Université

Research output: Contribution to journal › Article › peer-review

881 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Immunology and Microbiology